The tandemly linked p16(INK4a)MTS1 and p15(INK4b)/MTS2 genes on chromo
some 9, band p21 encode proteins that function as specific inhibitors
of the cyclin D-dependent kinases CDK4 and CDK6. This locus undergoes
frequent bi-allelic deletion in human cancer cell lines, suggesting th
at the encoded proteins may function as tumor suppressors. However, mo
re recent analysis of primary tumor samples has shown a much lower fre
quency of abnormalities affecting this region, raising doubt over the
importance of these proteins in human malignancies, Hemizygous deletio
ns and rearrangements of chromosome 9, band p21, are among the most fr
equent cytogenetic abnormalities detected in pediatric acute lymphobla
stic leukemia (ALL), occurring in approximately 10% of cases. To deter
mine if the p16(INK4a)/p15(INK4b) locus might be the target of these c
hromosomal lesions, we analyzed both genes in primary clinical samples
from 43 pediatric ALL patients using interphase fluorescence in situ
hybridization, Southern blot analysis, and the polymerase chain reacti
on. Deletions of p16(INK4a)/p15(INK4b) were identified in 18 of 20 cas
es with cytogenetically observed abnormalities of 9p and 5 of 23 with
apparently normal chromosomes 9p, with the majority containing bi-alle
lic deletions (16 homozygous/7 hemizygous). Although most homozygous d
eletions involved both genes, Southern blot analysis showed an interst
itial deletion in a single case that was confined to p16(INK4a), sugge
sting that p15(INK4b) was not the critical target gene in this case. S
equence analysis of both p16(INK4a) and p15(INK4b) in all seven cases
with hemizygous deletions failed to show mutations within the coding r
egions of the retained alleles. In this select group of patients, dele
tion of p16(INK4a)/p15(INK4b) was associated with T-cell phenotype, no
nhyperdiploid karyotype (<50 chromosomes), and poor event-free surviva
l. These findings indicate that deletion of the p16(INK4a)/p15(INK4b)
locus is one of the most common genetic abnormalities so far detected
in pediatric ALL, and that loss of one or more of these cell cycle kin
ase inhibitors is important in leukemogenesis. (C) 1995 by The America
n Society of Hematology.